Partial hepatectomy and liver transplantation are potentially curative treatments in selected patients with hepatocellular carcinoma (HCC). Unfortunately, a high postoperative tumor recurrence rate significantly decreases long-term survival outcomes. Among multiple prognostic factors, the presence of microvascular invasion (MVI) has increasingly been recognized to reflect enhanced abilities of local invasion and distant metastasis of HCC. Unfortunately, MVI can only currently be identified through histopathological studies on resected surgical specimens. Accurate preoperative tests to predict the presence of MVI are urgently needed. This paper reviews the current studies on incidence, pathological diagnosis, and classification of MVI; possible mechanisms of MVI formation; and preoperative prediction of the presence of MVI. Furthermore, focusing on how the postoperative management can be improved on histopathologically confirmed patients with HCC with MVI, and the potential roles of using predictive tests to estimate the risk of presence of MVI, helps in preoperative therapeutic decision-making in patients with HCC.
Introduction
Hepatocellular carcinoma (HCC) is one of the most common malignancies in the world. 1 This tumor has a tendency to invade intrahepatic blood vessels resulting in intrahepatic and extrahepatic metastases. 2 Although liver resection and transplantation are currently the most important treatments with curative potential in selected patients with HCC, 3 the long-term survival outcomes are still unsatisfactory because of high incidences of tumor recurrence and metastasis. 4 Macrovascular and microvascular invasion (MVI) in HCC are usually associated with more advanced tumor stage and disease progression. Macrovascular invasion with gross tumor thrombus can be diagnosed by medical imaging. Patients with macrovascular invasive HCC usually lose the chance to undergo curative liver resection or transplantation, and even when these treatments are given, they inevitably have bad long-term survival outcomes. 5 In contrast, up to date, the clinical significance of MVI has been underestimated, possibly because MVI has been thought to be a mild form of manifestation of tumor invasiveness, and can only be found by histopathological examination on postoperative surgical specimens. With increasing recognition of MVI and its adverse impact on prognosis, MVI has become a hot topic in research in HCC, 6 focusing on how postoperative management can be improved on the basis of histopathologically confirmed MVI, and the potential roles of using preoperative predictive models on therapeutic decision-making in patients with HCC.
Definition of MVI
The diagnostic criteria of MVI in patients with HCC have not been universally accepted. Sumie et al. proposed to diagnose MVI once tumor cells were found invading into portal or hepatic venous systems. They further classified MVI into three grades according to the number of MVI, that is, no MVI, mild MVI (1-5 MVI), and severe MVI (>5 MVI). 7 However, this method failed to take into account the distance between the invaded vessels and the edge of the tumor and whether the tumor had invaded other vascular systems, bile ducts, and lymphatic vessels. Roayaie et al. showed the presence of MVI in a vessel with a muscular wall and more than 5 MVI to be associated with increased tumor recurrence, while MVI at >1 cm away from the tumor predicted a worse postoperative survival outcome. On the basis of the presence/absence of these two microscopic features of MVI, they divided their patients with vascular invasion into five groups: group A, no MVI; B1, presence of MVI alone; B2, MVI with one aggressive feature; B3, MVI with two features; and C, macrovascular invasion. 8 After incorporating the data obtained from international and national studies on HCC, the Chinese Society of Pathology has recently proposed "A Guideline of Standardized Pathological Diagnosis of Primary Liver Cancer (2015 edition)". In this edition, the presence of MVI was described as "a cancer cell nest with >50 cells in the endothelial vascular lumen under microscopy". MVI was classified into three grades according to the number and distribution of MVI: M0, no MVI; M1 (the low-risk group), ≤5 MVI in adjacent liver tissue ≤1 cm away from the tumor; M2 (the highrisk group), >5 MVI or MVI in liver tissue >1 cm away from the tumor. 9 In a study, the authors, on the basis of the depth of invasion and the relationship between the histopathological tumor emboli and vascular wall, divided MVI into three types: adhesion type, invasion type, and breakthrough type, which in descending order, had decreased chances of long-term survival after surgery. The former one was classified as non-invasive MVI while the latter two as invasive MVI. 10 However, the clinical relevance of these histopathological classifications still needs to be validated.
Incidences of MVI
The reported incidences of MVI varied among previous reported studies. [6] [7] [8] In 2002, Lauwers et al. reported the incidence of MVI in surgically treated HCC patients to be 51.3%. 11 A systematic review showed the incidence to be between 15% and 57.1% in surgical specimens obtained after liver resection and transplantation. 6 The wide range of incidences of MVI is probably because of the varied criteria used to select patients for surgical treatment among different centers. The differences in tumor stages and degrees of invasive characteristics of HCC would affect the incidences of MVI. 6 On the basis of multicentric data of 1073 patients, Pawlik et al. reported the rates of MVI to be 25%, 40%, 55%, and 63% in patients with HCC <3, 3-5, 5-6.5, and >6.5 cm, respectively, which suggested a significant risk of the presence of MVI even in patients with small HCC. 12 This observation was confirmed by Du's study, in which 18.1% of surgically resected small HCC (n = 458, ≤3 cm) had MVI. 13 In liver transplantation for HCC within the Milan criteria, Onaca et al. showed the incidence of MVI to be 22.1% in 902 patients from 57 centers. 14 The incidence of MVI is also affected by the differences in diagnostic criteria used as mentioned earlier and by whether appropriate and careful sampling procedures have been carried out on the resected surgical specimens. Some studies showed that MVI could violate tumor capsules and invade into vessels ≥1 cm from the tumor capsules, and MVI was not evenly distributed in blood vessels around the adjacent liver parenchyma. 7, 8 The Chinese Society of Pathology has recommended a sampling process including the sites, distances, and volumes for tissue sampling from HCC surgical specimens in order to make more accurate pathological diagnoses, including the presence of MVI (Fig. 1) . 9 Although some authors even suggested tumor biopsy to make the diagnosis of MVI, the procedure has not been experimentally evaluated, as small tissue samples may be not sufficient to make the diagnosis and may increase the risk of needle tract tumor implantation. 6 Possible mechanisms of MVI Vascular invasion of HCC is a multi-step biological process involving many factors including the interactions of HCC with the microenvironment and the host status (immune, endocrine, and metabolism). 15 Such mechanisms have not been fully worked out, although tremendous efforts have been made in the area. Previous studies described the process in which cancer cells in primary liver tumor acquired the ability of the invasive phenotype by upregulation of certain oncogenes, inactivation of suppressor genes, and imbalance of immune genes. With loss of tissue integrity, these tumor cells invaded into the surrounding tissue, entered into blood vessels, and colonized on the invaded target organs, forming metastatic foci. 16 Several signaling pathways may be involved in the vascular invasion of HCC, such as the growth factor, Wnt/β-catenin, and RAS/RAF/MAPK. 17 Recently, the genetic landscape has been drawn by next-generation sequencing in capturing molecular alterations of HCC. 18 However, the abundant long non-coding RNAs (lncRNAs) transcribed from human genome remain limited. Recently, Yuan et al. utilized microarray analysis and found that lncRNAs were associated with MVI in HCC (termed as lncRNA MVIH). The lncRNA-MVIH was located and activated within the intron of the ribosomal protein S24 transcript, which then activated tumor-inducing angiogenesis and boosted tumor growth by inhibiting secretion of phosphoglycerate kinase 1.
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Within the cancer microenvironment, T-regulatory (Treg) cells are abundant in tumor tissues, and contribute to escape of cancer cells from immunosurveillance. 20 In Yang's report, the TGF-β-miR-34a-CCL22 signaling pathway induced Treg cells recruitment and promoted venous metastases of HCC. The hepatitis B virus (HBV) infection of liver microenvironment increased the activity of TGF-β signaling, inhibited the expression of miR-34a, Figure 1 Diagram of sampling sites in liver tumor specimens. Shown is the process of sampling of hepatocellular carcinoma specimens for histopathological examination. Firstly, one to two pieces are sampled at A, B, C, and D, and the ratio of tumor and adjacent liver tissue is 1:1. Secondly, two to three pieces are sampled at E. Thirdly, one to two pieces are sampled at F. Lastly, one to two pieces are sampled at G if the surgical margin is wide enough. Each piece is marked, and the volume is about and enhanced CCL22 production, resulting in recruitment of tumor-associated effector Treg cells and tumor progression. 21 
Clinical significance of histopathologically confirmed MVI
The presence of MVI as shown histopathologically predicts the risks of tumor recurrence and long-term survival after surgery.
6-8,10-13, 22 Lauwers et al. reported in 2002 that the presence of MVI was an independent risk factor of post-resectional prognosis. 11 Although very early HCC <2 cm is commonly associated with extremely favorable long-term outcomes after curative treatment, 23 early tumor recurrence also develops in a proportion of these patients as a consequence of MVI that persists after "curative treatment". 12 In the study reported by Yamashita et al., there were 43 patients with MVI in 149 patients (28.9%) who underwent hepatic resection for tumor ≤2 cm. The 1-year recurrence rates were 7.5% and 23.3% for patients without or with MVI, respectively (P = 0.01). 24 The authors speculated that surgical resection with a wide margin could better eradicate MVI adjacent to the tumor. However, such a decision to resect with a wide margin has to be made before treatment.
In liver transplantation for HCC, Mazzaferro et al. analyzed 1556 patients within the Milan criteria and found the 5-year recurrence rates to be 3.3% and 12.8% for patients without and with MVI, respectively. This significant difference was also identified in patients outside the Milan criteria (9.1% vs 39.9%). 25 In the study by Bertuzzo et al., the neutrophil-to-lymphocyte ratio, a systemic inflammation marker, and MVI were the only independent factors of recurrence and survival after liver transplantation. 26 As multiple and coexisting risk factors are involved in predicting long-term survival outcomes after treatment in patients with HCC, and no single factor is powerful enough to independently predict prognosis, establishing prognostic models, such as a nomogram or a scoring system, is a reasonable way to provide a more accurate prediction, or an estimation of the chance of long-term survival in an individual patient. Among all the currently available models, MVI is always an important variable. The nomogram proposed by Li et al. showed good performance for survival prediction in patients with HCC within the Milan criteria after hepatectomy. 27 An artificial neural networking model by Qiao et al. also showed optimal power for such a prediction. 28 Histopathologically confirmed MVI can also be used to identify high-risk HCC patients who will develop extrahepatic distant metastases after surgery. Early diagnosis for these metastatic lesions is difficult because they are usually asymptomatic. Li et al. established a predictive scoring system using different weights of the Cox regression analysis for patients with histopathologically confirmed MVI using tumor diameter and tumor encapsulation as the main parameters. The sensitivity and specificity of this scoring system in predicting extrahepatic metastases were 90.4% and 61.5%, respectively. This model is useful to identify the risk of extrahepatic metastases for an individual patient and helps early detection. 29 As the majority of distant metastases are in the lungs after HCC surgery, they further developed another nomogram using MVI as one of the predictive variables to predict lung metastases. 30 Currently, the effectiveness of postoperative adjuvant therapy in HCC remains to be confirmed, and protocols such as systemic chemotherapy, transarterial chemoembolization (TACE), and immunotherapy have not been universally accepted. [31] [32] [33] [34] [35] [36] [37] [38] [39] Histopathologically confirmed MVI can serve to select suitable patients for adjuvant therapy. A study showed post-transplantation adjuvant gemcitabine to be safe and effective in patients with HCC with MVI. 40 Another study showed the potential efficacy of sorafenib as adjuvant therapy after curative resection for HCC with MVI. 41 Recently, a prognostic nomogram that included MVI as a predictive factor was developed and served as a tool to identify the subgroup of patients who benefited significantly from adjuvant TACE. 42 Furthermore, Chen et al. found post-resectional cytokine-induced killer cell immunotherapy to be beneficial only for patients without MVI. 43 Potential significance of prediction of the presence of MVI Currently, the identification of MVI is still based on histopathological examination of resected surgical specimens. As many important therapeutic decisions should be made before surgery, the questions to ask are whether the risk of presence of MVI in an individual patient can be estimated preoperatively and whether such a prediction can be used to guide decisions to improve surgical management.
Preoperative prediction of the risk of MVI. Table 1 shows some of the current studies on the preoperative prediction of the risk of MVI in HCC.
Tumor characteristics. The diameter and number of HCC are important predictors of MVI. 44 In 245 patients who underwent liver transplantation, the incidences of MVI were 25% for tumor <2 cm, 31% for 2-4 cm, and 50% for >4 cm. 45 Kim et al. showed the incidence of MVI to be threefold greater in patients with two tumors than in patients with a single tumor. 46 Wu et al. suggested a non-smooth tumor margin on imaging to be independently associated with presence of MVI. 47 Kaibori et al. proposed an imaging-based score with tumor ≥5 cm, age under 65 years, and protein induced by vitamin K absence/antagonism-II (PIVKA-II) level ≥200 mAU/mL to be a reliable predictor for MVI. 48 In addition, local nodal metastasis, cell differentiation, body mass index, and other tumor characteristics have been reported to be significant predictors of MVI. 49 Unfortunately, these predictive methods have less value for early stage HCC, which are the major targets to improve the outcomes of surgical treatment. 44,50,51 Poté et al. suggested that the predictive value of PIVKA-II might be higher than AFP, particularly in patients with early stage HCC (hazard ratio: 3.5, 95% confidence interval: 1.08-11.8). Furthermore, the sensitivity and specificity of PIVKA-II, when combined with immunohistochemistry, were up to 87% and 90%, respectively. 50 HSP 70 and Eno-1 antibodies are also potential biomarkers for such predictions. 51 Unfortunately, these serum 52 Banerjee et al. recently reported on "radiogenomic venous invasion" that was the result of a combination of investigations using contrast-enhanced CT with biomarkers of MVI derived from an expression signature containing 91-gene related to "venous invasion" of HCC. The diagnostic accuracy, sensitivity, and specificity to predict the presence of MVI were 89%, 76%, and 94%, respectively. 53 Xu et al. utilized diffusionweighted MRI to analyze small HCC and found the sensitivity and specificity of low diffuse coefficient plus irregular peripheral enhancement for prediction of presence of MVI to be 66.7% and 78.6%, respectively. 54 Cheung et al. reported that 18 Ffludeoxyglucose-labeled positron emission tomography better predicted MVI, with sensitivity, specificity, and positive and negative predictive values being 55.2%, 69%, 64%, and 60.6%, Significance of microvascular invasion X Zhang et al.
respectively. 55 However, all these radiographical features are dependent on personal experience, and the results still need to be prospectively validated.
Gene tags. Some molecular biological indicators are considered to be associated with the presence of MVI, including gene expression levels, cell adhesion molecules, and angiogenesis-related factors. Mínguez et al. identified 35 gene tags (14 high and 21 low-expression genes) that were related to vascular invasion using whole-genome sequencing, with an accuracy of 69% for MVI prediction. 56 Ding et al. proposed that liver-intestinal cadherin, in combination with other adhesion molecules, predicted the presence of MVI and prognosis of patients with HCC. 57 Taking into account the low specificity, technological complicity, and high costs, these methods are still at the research stage and have not been clinically applied.
Clinical model. With the lack of any specific method, and with insufficient power of a single factor to predict MVI, a clinical model to combine multiple factors associated with the presence of MVI becomes an alternative strategy. Cucchetti et al. established an artificial neural networking model using non-invasive parameters that included preoperative AFP level and tumor number and size to predict the occurrence of MVI. 58 This model showed better predictive accuracy than the conventional statistical linear approach, although it requires specific software in clinical use. Lei et al. developed a nomogram from the data of 1004 patients who underwent hepatectomy for HBV-related HCC within the Milan criteria by incorporating tumor diameter, number, capsule, AFP, platelet level, HBV-DNA load, and typical imaging dynamic features on MRI. A nomogram score of ≤200 or >200 effectively identified patients with a low or a high risk of MVI. 59 In another scoring system, a score of ≥3 in patients with multinodular HCC was significantly associated with a higher MVI positive rate. 60 Potential use of preoperatively estimated MVI presence. The ability to have an accurate preoperative estimation of the risk of MVI is important to guide surgical management in patients with HCC for selection of the type of hepatectomy, width of surgical margins, and use of adjuvant or neoadjuvant therapy. Although there is still no report that shows the ability to predict MVI can improve the results of treatment, increasing studies have showed the potential significance of preoperative MVI prediction in surgical management of HCC patients ( Table 2) . It remains controversial as to whether anatomical resection (AR) really confers survival advantage over non-AR for HCC. 66, 67 A recent cooperation study on 269 patients who underwent hepatectomy in an Eastern Center and 274 patients in a Western Center for early stage HCC with cirrhosis showed that AR reduced early recurrence in patients with poorly differentiated tumor or with MVI. In contrast, there was no difference in long-term survival in patients with well-differentiated tumor or without MVI. Thus, AR might be more beneficial to patients with a high preoperative predicted risk of MVI. 61 The impact of the width of resection margin on long-term prognosis in patients with HCC is also controversial. 68, 69 As MVI can violate tumor capsules and invade vessels ≥1 cm from tumor capsules, 7, 8 a wide surgical margin (>1 cm) has been shown to decrease tumor recurrence in HCC patients with histopathological presence of MVI. 62 If the risk of MVI can be determined preoperatively, a reasonable decision can be made on the choice of AR or non-AR and on the width of surgical resection margins.
A reasonable criterion to include patients with HCC for liver transplantation should achieve an optimal balance between good surgical outcomes and donor shortage. 70 Recently, Mazzaferro 25 In another East and West cooperative study on 1024 patients with early stage HCC who underwent hepatectomy or liver transplantation, tumor size and number had more significance on long-term survival outcomes in hepatectomy patients, whereas the presence of MVI had more significant impact on transplant patients. In addition, when both procedures were evidently suitable, liver resection was more preferred for patients with MVI because of similar 5-year survival rates in these two procedures. 63 As such, the ability of preoperatively predicting the risk of MVI helps surgical decision-making.
The data supporting the role of intraoperative adjuvant therapy are insufficient. Brachytherapy with radioactive seed implantation for malignant tumors has been used for many years, showing promising therapeutic efficacy. Chen et al. performed a randomized controlled trial on patients who underwent liver resection and showed that implantation of 125 I particles in the hepatic cut surface significantly prolonged postoperative survival with mild side effects. A narrow surgical resection margin is frequently used in patients with large tumors, patients with tumors close to important intrahepatic structures, patients with tumors with infiltrating edges, or patients with cirrhosis. Early tumor recurrence can happen because of MVI being left behind after surgery, and implantation of 125 I particles can help to decrease this risk. 64 However, the use of this treatment would depend on the accurate preoperative estimation of the risk of MVI.
Currently, neoadjuvant therapy using systemic chemotherapy or TACE for resectable HCC is not recommended, 31, 32, 35, 71 as the therapy is ineffective and the delay in surgery can turn a resectable HCC to unresectable. Previous studies using neoadjuvant systemic chemotherapy failed to show any survival benefit after curative resection for HCC. 31, 32 Several randomized controlled trials failed to show any significant effectiveness of preoperative TACE in patients with resectable HCC. 72 Nishikawa et al. classified HCC patients who underwent preoperative TACE into TACE responders and non-responders. They concluded that the responders had better survival outcomes, and the presence of MVI was an adverse prognostic factor in these patients. 65 Of note, the information on the response to preoperative TACE could only be obtained after treatment. For patients who are estimated to have a high risk of the presence of MVI, whether neoadjuvant TACE can provide survival benefit is worthy of further studies.
Conclusions
The presence of MVI in HCC significantly decreases survival outcomes following hepatectomy or liver transplantation. The clinical significance of histopathologically confirmed MVI in current surgical practice includes prognostic estimation, close postoperative monitoring of recurrence, and use of adjuvant therapy. Accumulating evidences have shown that accurate and specific preoperative prediction is becoming increasingly possible by using clinicopathological models such as a nomogram. The ability to preoperatively predict the presence of MVI will help surgical decision-making and further improve surgical management for HCC.
